Zobrazeno 1 - 10
of 452
pro vyhledávání: '"A. Mezheyeuski"'
Autor:
Gemma Garcia‐Vicién, Núria Ruiz, Patrick Micke, José Carlos Ruffinelli, Kristel Mils, María Bañuls, Natalia Molina, Miguel A. Pardo, Laura Lladó, Artur Mezheyeuski, David G. Molleví
Publikováno v:
MedComm, Vol 5, Iss 12, Pp n/a-n/a (2024)
Abstract Colorectal liver metastases grow following different histologic growth patterns (HGPs), classified as desmoplastic and nondesmoplastic (dHGP, non‐dHGP), being the latter associated with worst prognosis. This study aimed to investigate the
Externí odkaz:
https://doaj.org/article/862271b0edc44328b9d16cf983070fe7
Autor:
Kang Wang, Ioannis Zerdes, Henrik J. Johansson, Dhifaf Sarhan, Yizhe Sun, Dimitris C. Kanellis, Emmanouil G. Sifakis, Artur Mezheyeuski, Xingrong Liu, Niklas Loman, Ingrid Hedenfalk, Jonas Bergh, Jiri Bartek, Thomas Hatschek, Janne Lehtiö, Alexios Matikas, Theodoros Foukakis
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-24 (2024)
Abstract Although metabolic reprogramming within tumor cells and tumor microenvironment (TME) is well described in breast cancer, little is known about how the interplay of immune state and cancer metabolism evolves during treatment. Here, we charact
Externí odkaz:
https://doaj.org/article/b1fcc99c167b4d128ce9d55c41851b89
Autor:
Iliana K. Kerzeli, Alexandros Kostakis, Polat Türker, Per-Uno Malmström, Tammer Hemdan, Artur Mezheyeuski, Douglas G. Ward, Richard T. Bryan, Ulrika Segersten, Martin Lord, Sara M. Mangsbo
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patie
Externí odkaz:
https://doaj.org/article/92d29f31336b4424a72603475b46d14c
Autor:
Anna Sandström Gerdtsson, Mattis Knulst, Johan Botling, Artur Mezheyeuski, Patrick Micke, Sara Ek
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThe immune microenvironment of non-small cell lung cancer (NSCLC) is heterogeneous, which impedes the prediction of response to immune checkpoint inhibitors. We have mapped the expression of 49 proteins to spatial immune niches in 33 NSCLC tu
Externí odkaz:
https://doaj.org/article/741394138eef44ecae9ba7ccc63aed84
Autor:
Backman, Max, Strell, Carina, Lindberg, Amanda, Mattsson, Johanna S.M., Elfving, Hedvig, Brunnström, Hans, O'Reilly, Aine, Bosic, Martina, Gulyas, Miklos, Isaksson, Johan, Botling, Johan, Kärre, Klas, Jirström, Karin, Lamberg, Kristina, Pontén, Fredrik, Leandersson, Karin, Mezheyeuski, Artur, Micke, Patrick
Publikováno v:
In European Journal of Cancer May 2023 185:40-52
Autor:
Mezheyeuski, Artur, Backman, Max, Mattsson, Johanna, Martín-Bernabé, Alfonso, Larsson, Chatarina, Hrynchyk, Ina, Hammarström, Klara, Ström, Simon, Ekström, Joakim, Mauchanski, Siarhei, Khelashvili, Salome, Lindberg, Amanda, Agnarsdóttir, Margrét, Edqvist, Per-Henrik, Huvila, Jutta, Segersten, Ulrika, Malmström, Per-Uno, Botling, Johan, Nodin, Björn, Hedner, Charlotta, Borg, David, Brändstedt, Jenny, Sartor, Hanna, Leandersson, Karin, Glimelius, Bengt, Portyanko, Anna, Ponten, Fredrik, Jirström, Karin, Micke, Patrick, Sjöblom, Tobias
Publikováno v:
In eBioMedicine February 2023 88
Autor:
Espen Basmo Ellingsen, Gergana Bounova, Iliana Kerzeli, Irantzu Anzar, Donjete Simnica, Elin Aamdal, Tormod Guren, Trevor Clancy, Artur Mezheyeuski, Else Marit Inderberg, Sara M. Mangsbo, Mascha Binder, Eivind Hovig, Gustav Gaudernack
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma. Translational research was conducted on patient-derived blood and ti
Externí odkaz:
https://doaj.org/article/e47b5805c551439fb54758c8276abab0
Autor:
Pedro García‐Gómez, Irene Golán, Mahsa S. Dadras, Artur Mezheyeuski, Claudia Bellomo, Kalliopi Tzavlaki, Anita Morén, Jordi Carreras‐Puigvert, Laia Caja
Publikováno v:
Molecular Oncology, Vol 16, Iss 9, Pp 1891-1912 (2022)
Glioblastoma (GBM) is the most aggressive and common glioma subtype, with a median survival of 15 months after diagnosis. Current treatments have limited therapeutic efficacy; thus, more effective approaches are needed. The glioblastoma tumoural mass
Externí odkaz:
https://doaj.org/article/bcbbc3ef2f3e4c95b309c91559fbcb09
Autor:
Artur Mezheyeuski, Max Backman, Johanna Mattsson, Alfonso Martín-Bernabé, Chatarina Larsson, Ina Hrynchyk, Klara Hammarström, Simon Ström, Joakim Ekström, Siarhei Mauchanski, Salome Khelashvili, Amanda Lindberg, Margrét Agnarsdóttir, Per-Henrik Edqvist, Jutta Huvila, Ulrika Segersten, Per-Uno Malmström, Johan Botling, Björn Nodin, Charlotta Hedner, David Borg, Jenny Brändstedt, Hanna Sartor, Karin Leandersson, Bengt Glimelius, Anna Portyanko, Fredrik Ponten, Karin Jirström, Patrick Micke, Tobias Sjöblom
Publikováno v:
EBioMedicine, Vol 88, Iss , Pp 104452- (2023)
Summary: Background: Cancer immunity is based on the interaction of a multitude of cells in the spatial context of the tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally improve the accuracy in predicting
Externí odkaz:
https://doaj.org/article/21d6bb4dde9a4bcc8ada77b8353d03fb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.